Zenosense, Inc. (ZENO) Begins Development of Lung Cancer Detection Device
Today before the opening bell, healthcare technology company Zenosense announced development efforts will commence on a detection device for lung cancer. Zenosense will be partnering with Sgenia, its development partner for an MRSA detection device, in these development operations. Full details are given in Zenosense’s Form 8-k, filed on July 24, 2014. The device calls for similar technology and principles (e.g., VOC signature detection) that are being used in the MRSA device. A revised development budget for both devices will require $1.41 million on top of the $527k that already has been spent. Lung cancer is the leading cause of…